Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023 LOS ANGELES, April 04, 2023 — Nexcella Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting […]
Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And Drug Administration (“FDA”) approved BCMA CAR-T Cell therapies. […]
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, liver response – in a total of 8 AL amyloidosis patients (an additional 2 patients maintaining 100% complete response). Additionally, Nexcella announced […]
Nexcella to Discuss Recent Positive NXC-201 Clinical Data In AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
LOS ANGELES, March 06, 2023 — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that Ilya Rachman, M.D., Ph.D., Nexcella Executive Chairman, and Gabriel Morris, Nexcella President, will discuss recent positive NXC-201 clinical data in AL […]
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis Nexcella on track to present 50-patient cohort multiple myeloma data later this year at a premier scientific forum LOS ANGELES, Feb. 27, 2023 — Nexcella, Inc. (“Nexcella”, “Company”), […]
Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S. Nexcella, Inc. initiates process of bringing NXC-201 to the United States by entering into an agreement with a well-known GMP cell therapy manufacturer that will supply Phase 1b/2 NXC-201 clinical trial material NXC-201 is in development for […]
Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of […]
Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached January 06, 2023 08:05 ET | Source: Nexcella, Inc. LOS ANGELES, CA, Jan. 06, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company engaged in the discovery […]
Nexcella, Inc announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
Nexcella, Inc announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting https://www.globenewswire.com/en/news-release/2022/12/28/2580204/0/en/Nexcella-Inc-announces-poster-presentation-at-the-European-Society-for-Blood-and-Marrow-Transplantation-and-European-Hematology-Association-5th-Annual-European-CAR-T-cell-Meeting.html Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023 December 28, 2022 08:05 ET | Source: […]
Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
December 14, 2022 08:05 ET | Source: Nexcella, Inc. Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) https://www.globenewswire.com/news-release/2022/12/14/2573649/0/en/Nexcella-Inc-in-licenses-NXC-201-BCMA-targeted-Next-Generation-CAR-T-Therapy-Demonstrating-High-Complete-Response-Rate-in-Heavily-Pre-Treated-Multiple-Myeloma-71-Complete-Responses.html LOS ANGELES, CA, Dec. 14, 2022 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical […]